Published online Aug 26, 2023. doi: 10.12998/wjcc.v11.i24.5823
Peer-review started: June 13, 2023
First decision: July 7, 2023
Revised: July 16, 2023
Accepted: July 28, 2023
Article in press: July 28, 2023
Published online: August 26, 2023
Processing time: 73 Days and 0.2 Hours
This is the first report of an ROS1-CENPW fusion gene in pancreatic malignancies.
A 77-year-old woman with a pancreatic tumor and multiple liver metastases was admitted to our hospital. Genetic testing revealed the presence of the ROS1-CENPW fusion gene, a rare fusion gene that has not been previously reported in the field of pancreatic cancer. The patient received crizotinib plus AG (albumin paclitaxel plus gemcitabine) chemotherapy. After treatment, the patient’s condi
The ROS1-CENPW gene treatment regimen used in this case is an excellent treatment option that provides new hope for patients with advanced pancreatic cancer and similar genetic mutations. To date, owing to the rarity of the ROS1-CENPW fusion gene, our team has encountered only a single case. Therefore, the efficacy of crizotinib plus AG chemotherapy in patients with pancreatic acinar cell carcinoma harboring the ROS1-CENPW fusion gene requires further validation.
Core Tip:ROS1-CENPW is a novel fusion gene locus in pancreatic acinar cell carcinoma that has not been previously reported. We detected this rare fusion gene in a 77-year-old female patient with pancreatic acinar cell carcinoma. We adopted the treatment regimen of crizotinib combined with AG chemotherapy (gemcitabine 1000 mg/m2 plus albumin paclitaxel 125 mg/m2). A good therapeutic effect was achieved.